Leqembi
In Brief This Week: Mount Sinai, AAVantgarde Bio, Lantern Pharma, Exegenesis Bio, AlveoGene
News items for the weeks of Nov. 25 and Dec. 2, 2024.
EMA's CHMP Now Recommends Approval for Eisai, Biogen's Alzheimer's Drug Leqembi in Europe
The agency had previously recommended against marketing authorization for the Alzheimer's drug but reconsidered after a review.
Eisai Completes Rolling BLA Submission for Subcutaneous Leqembi Maintenance Treatment
Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.
In Brief This Week: Hologic, Clinical Microbiomics, Eisai, Biogen, University of Michigan, Dizal
News items for the week of Oct. 14, 2024.
NICE Doesn't Recommend Biogen, Eisai's Alzheimer's Drug in Draft Guidance Despite MHRA Nod
After considering the data on Leqembi, the agency found that the four-to-six month slowing of disease progression wasn't enough benefit to justify its costs.
Jul 31, 2024
Jul 29, 2024
Feb 8, 2024